Art. -Nr.: HY-N0169

Hyodeoxycholic acid

Name: Hyodeoxycholic acid
Brand: MedChemExpress
SKU: HY-N0169
Price: 25.00 USD
Availability: InStock
Rating: 5 (7 reviews)

(Synonyms: HDCA)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC₅₀ of 31.6 µM in CHO cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.94%
CAS. Nr.: 83-49-8
Formel: C₂₄H₄₀O₄
Molecular Weight:392.57

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Hyodeoxycholic acid Chemical Structure

CAS. Nr.: 83-49-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC₅₀ of 31.6 µM in CHO cells.

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	31.6 μM Compound: 10, HDCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
HEK-293T	EC₅₀	>150 μM Compound: HDCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	>50 μM Compound: HDCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HT-29	IC₅₀	>80 μM Compound: 1; HDCA	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 27448915]
PC-3M	IC₅₀	>80 μM Compound: 1; HDCA	Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay	[PMID: 27448915]

In Vitro

Hyodeoxycholic acid is a secondary hydrophilic bile acid formed in the small intestine by the gut flora, and acts as an agonist of TGR5, with an EC₅₀ of 31.6 μM in CHO cells^[1]. Hyodeoxycholic acid (50, 100 μM) increases the expression of genes (Abca1, Abcg1, and Apoe) involved in cholesterol efflux in RAW 264.7 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

Hyodeoxycholic acid (HDCA; 1.25% (wt/wt)) obviously decreases fat mass and increases lean mass but does not raise the serum levels of any organ toxicity markers in LDLRKO mice. Hyodeoxycholic acid inhibits atherosclerotic lesion formation in LDLRKO at multiple sites, improves plasma lipoprotein profiles, decreases plasma glucose level and intestinal cholesterol absorption efficiency and increases daily cholesterol excretion through fecal output. Hyodeoxycholic acid also improves HDL function as measured by a cholesterol efflux assay^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 83-49-8
Appearance Solid
Molecular Weight 392.57
Formel C₂₄H₄₀O₄
Color White to off-white
SMILES

C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Synonyms

HDCA
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (7)

All WBRT-PCRIHCIF

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cell Host Microbe

Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease. [Abstract]

2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719
J Adv Res

Hyodeoxycholic acid relieves neuropathic pain by activating farnesoid X receptor signaling. [Abstract]

2025 Jul 11:S2090-1232(25)00543-0. PMID: 40653266

Hyodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jul 11:S2090-1232(25)00543-0. [Abstract]

Representative immunoblots treated with Hyodeoxycholic acid (HDCA) (20 mg/kg, i.g.).

Hyodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jul 11:S2090-1232(25)00543-0. [Abstract]

PWT and PWL of mice following Hyodeoxycholic acid (HDCA) (20 mg/kg, i.g.) treatment, relative expression levels of FXR mRNA.

Hyodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jul 11:S2090-1232(25)00543-0. [Abstract]

Immunohistochemical staining of FXR + cells and Alcian Blue staining in the distal ileum treated with Hyodeoxycholic acid (HDCA) (20 mg/kg, i.g.).

Hyodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jul 11:S2090-1232(25)00543-0. [Abstract]

Immunofluorescence staining and mean fluorescence intensity of Mucin-2 treated with Hyodeoxycholic acid (HDCA) (20 mg/kg, i.g.).
Redox Biol

Hyodeoxycholic acid attenuates atherosclerosis by antagonizing FXR and modulating the PD-1/mTORC1 signaling axis. [Abstract]

2026 May:92:104096. PMID: 41775219
Cell Death Differ

Gut-derived hyodeoxycholate reprograms the spleen-eye immunometabolic axis to suppress autoimmune uveitis. [Abstract]

2026 Mar 11. PMID: 41813862
J Anim Sci Biotechnol

2026 Jul 6;17(1):140. PMID: 42402612
Transl Psychiatry

TGR5 dysfunction underlies chronic social defeat stress via cAMP/PKA signaling pathway in the hippocampus. [Abstract]

2025 Oct 6;15(1):366. PMID: 41053031

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (254.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5473 mL

12.7366 mL

25.4732 mL

5 mM

0.5095 mL

2.5473 mL

5.0946 mL

10 mM

0.2547 mL

1.2737 mL

2.5473 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. [Content Brief]

[2]. Shih DM, et al. Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice. FASEB J. 2013 Sep;27(9):3805-17. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5473 mL	12.7366 mL	25.4732 mL	63.6829 mL
	5 mM	0.5095 mL	2.5473 mL	5.0946 mL	12.7366 mL
	10 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3683 mL
	15 mM	0.1698 mL	0.8491 mL	1.6982 mL	4.2455 mL
	20 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1841 mL
	25 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	30 mM	0.0849 mL	0.4246 mL	0.8491 mL	2.1228 mL
	40 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2737 mL
	60 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0614 mL
	80 mM	0.0318 mL	0.1592 mL	0.3184 mL	0.7960 mL
	100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL

Bioz

Keywords

Hyodeoxycholic acid

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hyodeoxycholic acid

Publications Citing Use of MedChemExpress (MCE) Hyodeoxycholic acid

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen